Product Description
Reteplase (BM 06.022; r-PA) is a recombinant peptide which consists of the kringle 2 and protease domains of human tissue-type plasminogen activator. It has been developed as a thrombolytic treatment for acute myocardial infarction (AMI). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8891469/)
Mechanisms of Action: PLA Activator
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Chiesi
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Ischemic Stroke|Thrombosis
Phase 2: Pulmonary Embolism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05295173 |
CRAD-001-03 | P3 |
Completed |
Ischemic Stroke |
2023-06-22 |
8% |
2023-09-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2019-002124-32 |
READY 1 | P3 |
Active, not recruiting |
Thrombosis |
2021-12-04 |
20% |
2022-03-13 |
Treatments |
CTR20191034 |
CTR20191034 | P2 |
Recruiting |
Pulmonary Embolism |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20213141 |
CTR20213141 | P2 |
Recruiting |
Thrombosis |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20213294 |
CTR20213294 | P3 |
Completed |
Ischemic Stroke |
2023-06-22 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/05/2023 |
News Article |
Reteplase Market 2023 Statistics, Share Price, Growth Prospects, Industry Trends till 2031 |
|
09/25/2023 |
News Article |
[2023-2031] Sensor Integration Gateway Market Size, Research Report |
|
10/04/2022 |
News Article |
Insights on the Clot Buster Drugs Global Market to 2027 - Increasing Prevalence of Cardiovascular Diseases Such as Heart Attacks and Strokes is Driving Growth |
|
09/22/2022 |
News Article |
Global Clot Buster Drugs Market Report to 2027 - Featuring F. Hoffmann-La Roche, Taj Pharmaceuticals and Eumedica Pharmaceuticals Among Others |